Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Aegerion Pharmaceuticals, Inc.
Case Number:
1:13-cv-11785
Court:
Nature of Suit:
Other Statutes: False Claims Act
Judge:
Firms
- Anderson & Kreiger
- Berman Tabacco
- Choate Hall
- Delaney Kester
- Delaney & Kester
- Donnelly Conroy
- Hogan Lovells
- Huggard Law LLC
- Libby Hoopes
- Lowey Dannenberg
- Morgan Lewis
- Nelson Mullins
- Nutter McClennen
- Post & Schell
- Pugsley Wood
- Ryan Litigation & Advocacy
Companies
Sectors & Industries:
-
May 24, 2019
FCA Suit Against Ex-Aegerion Execs Is Likely To Live On
A False Claims Act case against former executives of newly bankrupt Aegerion Pharmaceuticals Inc. will likely survive a motion to dismiss, a Boston federal judge said Friday, suggesting the suit can move forward even though the government settled claims against the company and declined to intervene against the executives.
-
June 19, 2018
Former Aegerion Execs Say FDA Approval Negates FCA Case
Former executives at Aegerion Pharmaceuticals Inc. argued Tuesday that a False Claims Act case against them ignores a federal regulatory program that gave marketers and doctors explicit permission to recommend an expensive cholesterol drug to people who did not have the rare genetic disorder it was created for.
-
March 16, 2018
Aegerion Placed Under Supervision In Misbranding Settlement
A federal judge on Friday appointed a special master to keep a watchful eye on Aegerion Pharmaceuticals Inc. as it faces court-ordered audits and the payment of $36 million to patients who were unnecessarily prescribed its expensive cholesterol drug and to government health programs that footed the bill.
-
January 30, 2018
Aegerion Sentenced To Pay Patients In Twist On $36M Plea
Patients harmed by a specialty cholesterol drug they were unnecessarily prescribed will get a slice of a $36 million forfeiture from Aegerion Pharmaceuticals Inc. instead of the government, a Massachusetts federal judge decided Tuesday in a criminal sentencing.